Alogliptin is an oral antidiabetic medication primarily used to manage type 2 diabetes mellitus. It works by selectively inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which increases the levels of incretin hormones in the body. These incretins stimulate insulin release from the pancreas in response to meals and reduce glucagon secretion, helping lower blood glucose levels. Alogliptin can be used as monotherapy in patients who are not adequately controlled by diet and exercise alone. It is also commonly prescribed in combination with other antidiabetic agents, such as metformin or sulfonylureas, to achieve better glycemic control. The drug is known for its generally favorable safety profile, with a low risk of causing hypoglycemia compared to some other antidiabetic medications. It can help improve long-term glycemic markers like HbA1c in patients with type 2 diabetes. Alogliptin is suitable for use in adults with varying degrees of renal function, with dose adjustments recommended for certain patients. Its once-daily dosing regimen improves patient compliance and convenience. Overall, alogliptin supports comprehensive diabetes management by enhancing insulin secretion, controlling postprandial glucose, and complementing lifestyle interventions.
